|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 289.33 USD | -0.10% |
|
-2.00% | +11.01% |
| 06-17 | Saudi Arabia Signs Multiple Healthcare Deals, Partnerships at BIO 2025 | MT |
| 06-13 | Alert on Amgen documentary about bad cholesterol withdrawn | RE |
| Capitalization | 156B 135B 127B 116B 214B 13,466B 241B 1,501B 576B 6,166B 584B 571B 22,722B | P/E ratio 2025 * |
21.4x | P/E ratio 2026 * | 19.3x |
|---|---|---|---|---|---|
| Enterprise value | 201B 174B 164B 149B 276B 17,368B 311B 1,936B 742B 7,953B 753B 737B 29,306B | EV / Sales 2025 * |
5.69x | EV / Sales 2026 * | 5.42x |
| Free-Float |
99.85% | Yield 2025 * |
3.31% | Yield 2026 * | 3.48% |
More valuation ratios
* Estimated data
More news
Last Transcript: Amgen Inc.
More recommendations
More press releases
More news
| 1 day | -0.10% | ||
| 1 week | -2.00% | ||
| Current month | +0.40% | ||
| 1 month | +5.21% | ||
| 3 months | -8.16% | ||
| 6 months | +9.85% | ||
| Current year | +11.01% |
| 1 week | 286.6 |  | 298.77 |
| 1 month | 269.1 | | 299.49 |
| Current year | 257.05 | | 335.88 |
| 1 year | 253.3 | | 346.85 |
| 3 years | 211.71 | | 346.85 |
| 5 years | 198.64 | | 346.85 |
| 10 years | 130.09 | | 346.85 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 62 | 30/04/2012 |
Peter Griffith
DFI | Director of Finance/CFO | 66 | 31/12/2019 |
James Bradner
CTO | Chief Tech/Sci/R&D Officer | 52 | 17/12/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CHM | Chairman | 62 | 31/12/2012 |
Tyler Jacks
BRD | Director/Board Member | 64 | 31/12/2011 |
Robert Eckert
BRD | Director/Board Member | 70 | 31/12/2011 |
| Name | Weight | AuM | 1st Jan change | |
|---|---|---|---|---|
| 5.08% | 137 M€ | -9.33% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.10% | -2.00% | -6.63% | +23.27% | 156B | ||
| -2.84% | -6.91% | -13.91% | +162.20% | 685B | ||
| -0.62% | -4.65% | +1.36% | -11.61% | 360B | ||
| -0.10% | -3.02% | +7.65% | +34.00% | 327B | ||
| -2.58% | -7.83% | -52.12% | +25.00% | 326B | ||
| -0.27% | -3.86% | +3.72% | -14.84% | 255B | ||
| -0.34% | -2.34% | +0.59% | +19.15% | 228B | ||
| -1.52% | -5.41% | -16.18% | +3.36% | 217B | ||
| -0.29% | -3.24% | -39.03% | -6.57% | 199B | ||
| +0.38% | -2.32% | -13.59% | -48.48% | 136B | ||
| Average | -0.83% | -3.99% | -12.81% | +18.55% | 288.83B | |
| Weighted average by Cap. | -1.23% | -4.60% | -12.67% | +42.65% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 35.25B 30.6B 28.83B 26.22B 48.41B 3,051B 54.66B 340B 130B 1,397B 132B 129B 5,149B | 35.89B 31.15B 29.34B 26.69B 49.28B 3,106B 55.64B 346B 133B 1,422B 135B 132B 5,241B |
| Net income | 6.73B 5.84B 5.5B 5.01B 9.24B 583B 10.43B 64.94B 24.9B 267B 25.25B 24.71B 983B | 7.53B 6.53B 6.15B 5.6B 10.34B 651B 11.67B 72.63B 27.85B 298B 28.24B 27.63B 1,099B |
| Net Debt | 45.08B 39.13B 36.86B 33.53B 61.9B 3,902B 69.89B 435B 167B 1,787B 169B 166B 6,584B | 39.09B 33.94B 31.96B 29.07B 53.68B 3,383B 60.6B 377B 145B 1,549B 147B 144B 5,709B |
More financial data
* Estimated data
Employees
28,000
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 20/06/25 | 289.33 $ | -0.10% | 6,801,395 |
| 18/06/25 | 289.63 $ | -0.14% | 2,026,814 |
| 17/06/25 | 290.05 $ | -1.86% | 2,515,461 |
| 16/06/25 | 295.56 $ | +0.12% | 2,047,619 |
| 13/06/25 | 295.22 $ | -0.70% | 2,191,296 |
Delayed Quote Nasdaq, June 20, 2025 at 09:00 pm
More quotes
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
33
Last Close Price
289.33USD
Average target price
314.70USD
Spread / Average Target
+8.77%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- AMGN Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition